Overview

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Status:
Not yet recruiting

Trial end date:
2026-04-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Klus Pharma Inc.

Collaborator:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Treatments:

Carboplatin
Osimertinib
Pembrolizumab